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Summary
Background Small benign insulinomas are hard to localise, leading to diﬃ  culties in planning of surgical interventions. 
We aimed to prospectively assess the insulinoma detection rate of single-photon emission CT in combination with CT 
(SPECT/CT) with a glucagon-like peptide-1 receptor avid radiotracer, and compare detection rates with conventional 
CT/MRI techniques.
Methods In our prospective imaging study, we enrolled adults aged 25–81 years at centres in Germany, Switzerland, 
and the UK. Eligible patients had proven clinical and biochemical endogenous hyperinsulinaemic hypoglycaemia 
and no evidence for metastatic disease on conventional imaging. CT/MRI imaging was done at referring centres 
according to standard protocols. At three tertiary nuclear medicine centres, we used whole body planar images and 
SPECT/CT of the abdomen up to 168 h after injection of ¹¹¹In-[Lys40(Ahx-DTPA-¹¹¹In)NH2]-exendin-4 (¹¹¹In-DTPA-
exendin-4) to identify insulinomas. Consenting patients underwent surgery and imaging ﬁ ndings were conﬁ rmed 
histologically.
Findings Between Oct 1, 2008, and Dec 31, 2011, we recruited 30 patients. All patients underwent ¹¹¹In-DTPA-
exendin-4 imaging, 25 patients underwent surgery (with histological analysis), and 27 patients were assessed with 
CT/MRI. ¹¹¹In-DTPA-exendin-4 SPECT/CT correctly detected 19 insulinomas and four additional positive lesions 
(two islet-cell hyperplasia and two uncharacterised lesions) resulting in a positive predictive value of 83% (95% CI 
62–94). One true negative (islet-cell hyperplasia) and one false negative (malignant insulinoma) result was identiﬁ ed 
in separate patients by ¹¹¹In-DTPA-exendin-4 SPECT/CT. Seven patients (23%) were referred to surgery on the basis 
of ¹¹¹In-DTPA-exendin-4 imaging alone. For 23 assessable patients, ¹¹¹In-DTPA-exendin-4 SPECT/CT had a higher 
sensitivity (95% [95% CI 74–100]) than did CT/MRI (47% [27–68]; p=0·011).
Interpretation ¹¹¹In-DTPA-exendin-4 SPECT/CT could provide a good second-line imaging strategy for patients with 
negative results on initial imaging with CT/MRI.
Funding Oncosuisse, the Swiss National Science Foundation, and UK Department of Health.
Introduction
Benign insulinomas are small neuroendocrine tumours 
that are nearly always located in the pancreas and are the 
most common cause of endogenous hyperinsulinaemic 
hypoglycaemia in adult patients without diabetes.1 
Conventional imaging (ie, CT/MRI) and, if available, 
endoscopic ultrasound  form the basis of localisation and 
diagnosis of suspected insulinoma.2–5 However, because 
of the small size of these tumours, localisation with 
conventional procedures has notable diagnostic 
diﬃ  culties.6 Methods such as selective intra-arterial 
calcium stimulation and venous sampling (ASVS) have a 
better sensitivity than do conventional techniques, but 
are invasive procedures with a concomitant risk of 
complications.6–8
As somatostatin receptor expression is low in benign 
insulinomas,9 detection rates with somatostatin receptor 
scintigraphy are low, and thus development of a new 
receptor targeted imaging technique for this type of 
neuroendocrine tumour will be important. Data from 
in-vitro studies suggest that benign insulinomas have a 
very high density of glucagon-like peptide-1 receptors 
(GLP-1R) that might be used as speciﬁ c targets for in-vivo 
receptor imaging.10
GLP-1 or its analogues, liraglutide and exenatide, 
enhance insulin secretion by β cells and have been 
introduced for treatment of type 2 diabetes.11,12 Several 
GLP-1-like radioligands retaining high binding aﬃ  nity to 
GLP-1R have been developed, including the speciﬁ c ligand 
[Lys⁴⁰(Ahx-DOTA)NH2]exendin-4 and [Lys⁴⁰(Ahx-DTPA)
NH2]exendin-4 labelled with indium-111 (¹¹¹In-DOTA-
exendin-4 and ¹¹¹In-DTPA-exendin-4) and [Lys⁴⁰(Ahx-
HYNIC)NH2]exendin-4 labelled with technetium-99m 
(⁹⁹mTc-HYNIC-exendin-4).13–17 In a proof-of-principle 
study,18 ¹¹¹In-DOTA-exendin-4 was given to six patients 
with endogenous hyperinsulinaemic hypoglycaemia. 
Single-photon emission CT in combination with CT 
(SPECT/CT) detected the lesion in all six patients whereas 
conventional imaging appropriately located the tumour in 
only one patient and endosonography was positive in four 
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patients. Notably, in-vitro GLP-1R autoradiography of the 
surgical specimen showed a high density of GLP-1R in all 
six insulinomas.18 Similarly, ⁹⁹mTc-HYNIC-exendin-4 
showed promising results in a recent report.15
A curative treatment approach for insulinoma relies 
on surgical removal of the tumour. Therefore, 
identiﬁ cation of the precise preoperative location of the 
insulinoma is crucial to reduce the extent of the surgical 
intervention and allow for preservation of pancreatic 
tissue.3,6 The results of the proof-of-principle study18 
showed that GLP-1R imaging is capable of localising 
insulinomas in vivo.
Our study aimed to determine the insulinoma detection 
rates of ¹¹¹In-DTPA-exendin-4 SPECT/CT and con-
ventional imaging, and to assess whether ¹¹¹In-DTPA-
exendin-4 SPECT/CT changes clinical management in 
patients with negative conventional imaging.
Methods
Study design and patients
In our prospective multicentre imaging study, we 
screened patients with suspected hyperinsulinaemic 
hypoglycaemia (positive Whipple triad) at tertiary referral 
centres in Switzerland (University of Basel Hospital, 
University of Berne Hospital, Kantonsspital Lucerne, and 
Kantonsspital St Gallen), Germany (University Hospital 
Freiburg), and the UK (Royal Free Hospital) according to 
the present guidelines.19 We enrolled adults aged 
25–81 years with biochemically proven endogenous 
hyperinsulinaemic hypoglycaemia in the fasting state (ie, 
neuroglycopenic symptoms in the fasting state with low 
plasma glucose, inappropriately high serum insulin and 
C-peptide concentrations, and a negative screening for 
sulfonylurea).20 In addition, to exclude patients with 
evidence of malignant insulinoma, local conventional 
imaging (CT/MRI) had to have shown no or only one 
suspicious lesion. We excluded pregnant women, patients 
with allergies to exendin-4, and patients with renal 
insuﬃ  ciency (blood creatinine concentrations 
>140 μmol/L). All patients who fulﬁ lled inclusion criteria 
(reviewed by EC) were referred to one of the three tertiary 
nuclear medicine referral centres (University of Basel 
Hospital, Basel, Switzerland; University Hospital 
Freiburg, Freiburg, Germany; University College London 
Hospital, London, UK) for ¹¹¹In-DTPA-exendin-4 
imaging. All three centres used the same inclusion and 
exclusion criteria and the same radiotracer and SPECT/CT 
imaging protocol. The Swiss study was registered with 
ClinicalTrials.gov, number NCT00937079.
The study was approved by the local institutional 
review board of each participating institution, and 
patients provided written consent in accordance with 
provisions of the Declaration of Helsinki.
Procedures
Conventional imaging was done by the referring centres, 
and included triple phase multidetector CT and MRI 
with 1·5 T or 3·0 T systems and a dedicated circular 
polarised body array for signal reception. Minimum 
pulse sequence requirements were multiplanar (axial 
and coronal) fast spin echo T2-weighted images and axial 
multiphasic T1-weighted gradient echo images before 
and after the administration of a gadolinium-containing 
contrast agent. Additional (optional) pulse sequences 
included axial gradient dual echo images and axial 
diﬀ usion weighted images. The appendix summarises 
CT and MR imaging procedures undertaken at the 
referral centres.
We did GLP-1R imaging within 2 months of con-
ventional imaging. Synthesis and labelling of ¹¹¹In-
DTPA-exendin-4 has been published elsewhere.13 
We monitored blood sugar concentrations 15 min, 
40 min, 60 min, 120 min, 180 min, and 240 min after the 
injection of ¹¹¹In-DTPA-exendin-4 and glucose (5%) 
infusion was administered if needed.
Total-body planar images and single-photon emission 
CT (SPECT) in combination with CT scans of the 
abdomen were acquired at 4 h and 3–5 days after injection 
of 8–14 μg (80–128 MBq) ¹¹¹In-DTPA-exendin-4. The 
radiopharmaceutical was intravenously injected over 
4–5 min. We did imaging with a combined SPECT/CT 
unit (Symbia T2 [Siemens Medical Systems, Erlangen, 
Germany], Inﬁ nia Hawkeye [GE Healthcare, Chalfont St 
Giles, UK], or Bright View XCT [Philips Healthcare, Best, 
Netherlands]) equipped with a medium-energy, parallel-
hole collimator.18 We used low-dose CT imaging (130 kVp, 
40 mAs) to correct for attenuation eﬀ ects and to provide 
better anatomical localisation of SPECT ﬁ ndings.
We regarded histological diagnosis as the gold standard 
for detection of insulinomas. All conventional scans were 
independently reported by experienced dedicated 
radiologists at the referral centres. Two experienced 
nuclear medicine physicians (DW and FF) visually 
assessed GLP-1R scans. All tissue samples with evidence 
of adult nesidioblastosis were reviewed by an experienced 
pathologist (AP). The radiologists, nuclear medicine 
physicians, and pathologists were masked to the results 
of other diagnostic tests but were aware of the patients’ 
clinical histories.
Statistical analysis
We regarded positive imaging tests that showed 
consistency between imaging, surgery, and histological 
analysis (positive for insulinoma) as true positives. 
The only exception was made in patients with several 
lesions. In such patients, the imaging test was regarded 
as true positive if at least one insulinoma was correctly 
localised (per patient-based analysis).
For point estimates of sensitivity, speciﬁ city, and 
positive predictive value (PPV), we calculated 95% CI 
according to the method by Agresti and Coull.21 For point 
estimates of the diagnostic odds ratio, we derived 95% CI 
assuming an approximate normal distribution of the 
logarithm of the odds ratio.22
See Online for appendix
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To compare diﬀ erences between imaging techniques, on 
the basis of a small pilot study18 of six patients we assumed 
¹¹¹In-DTPA-exendin-4 would have a 25% increased 
detection rate of insulinoma than con ventional CT/MRI 
imaging. With a power of 80% and α of 5%, we planned to 
enrol 30 patients assuming a dropout rate of 10%.
We assessed signiﬁ cance of the diﬀ erence in sensitivity 
and speciﬁ city between ¹¹¹In-DTPA-exendin-4 SPECT/CT 
and CT/MRI by use of an exact binomial test for 
dependent proportions as introduced by Mosteller.23 
For comparison of PPVs, we applied the generalised 
score test.24 Because estimation of odds ratios was either 
very imprecise (for the GLP-1R imaging) or not possible 
(for CT/MRI), we did not consider a comparison of the 
odds ratios. All analyses were done with R, version 2.15.3.
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, analysis, interpretation, or writing of the 
report. The corresponding author, EC, and FF had full 
access to all the data in this study and had ﬁ nal 
responsibility for the decision to submit the manuscript.
Results
Between Oct 1, 2008, and Dec 31, 2011, we recruited 
30 consecutive patients in neuroendocrine tertiary 
referral centres (table 1) and referred them to three 
tertiary nuclear medicine centres. All patients underwent 
a fasting test. After 4–72 h of fasting, all patients had 
symptoms of neuroglycopenia (eg, confusion or 
unconsciousness up to seizure) with low plasma glucose 
concentrations and inadequately high concentrations of 
insulin and C-peptide (table 1). 25 (83%) of 30 patients 
had deﬁ nite surgical histological diagnosis and were 
included in the main assessments (ﬁ gure 1).
CT/MRI assessments were done for 23 (92%) of these 
25 patients (ﬁ gure 1). In two patients, CT and MRI 
assessments were not done because endoscopic ultrasound 
was available. Insulinoma was correctly diagnosed by CT/
MRI in nine of 19 patients (47% sensitivity, 95% CI 27–68), 
with a PPV of 100% (95% CI 66–100). Figure 2 shows the 
contingency table for conventional imaging and histology.
11 (44%) of 25 patients had endoscopic ultrasound, 
which identiﬁ ed lesions in eight patients. Endoscopic 
ultrasound localised the insulinoma in seven (88%, 
95% CI 66–100) of these patients and islet-cell hyperplasia 
in the other patient (ie, a false positive). Two patients had 
a true negative result (islet-cell hyperplasia and no ﬁ nal 
histological diagnosis) and one patient had a false 
negative result with endoscopic ultrasound.
Seven (28%) of 25 patients underwent ASVS. The correct 
vascular territory of the insulinoma was detected in ﬁ ve 
(71%) of these patients. Two patients with positive results 
after ASVS did not show any evidence for an insulinoma 
during or after surgery (false positive). Histological 
assessment showed islet-cell hyperplasia in one patient 
and no pathological ﬁ ndings in the other patient.
The labelling yield of ¹¹¹In-DTPA-exendin-4 was more 
than 95% with a speciﬁ c activity of 90 GBq/μmol and a 
radiochemical purity of 92%. The median decrease in 
blood glucose level was 1·3 mmol/L (IQR 0·8–2·1; range 
0·0–2·6 mmol/L) after injection of ¹¹¹In-DTPA-exendin-4. 
The nadir of blood glucose concentrations occurred 
40 min after injection. 20 (67%) of 30 patients required an 
exogenous glucose infusion (5%) for a maximum of 
90 min. No serious episodes of hypoglycaemia occurred. 
The appendix shows a summary of blood glucose ﬁ ndings 
of each patient before and after injection of ¹¹¹In-DTPA-
exendin-4. We noted no other side-eﬀ ects.
The longest residence times of ¹¹¹In-DTPA-exendin-4 
were noted in the tumour and kidneys (ﬁ gure 3), and the 
clearance of the radiotracer occurred exclusively via the 
kidneys. For 20 (80%) of 25 patients, GLP-1R imaging 
Participants (n=30)
Age, years 55 (39–75; 25–81)
Sex
Male 11 (37%)
Female 19 (63%)
Biochemical assessments at the end of 
the fasting test
Duration of fasting, h 24 (13–32; 4–72)
Plasma glucose, mmol/L 1·9 (1·7–2·2; 1·0–3·0)
C-peptide, nmol/L 1·11 (0·44–1·90; 0·23–2·50)
Insulin, mU/L 11·0 (6·7–22·0; 1·9–38·0)
Data are median (IQR; range) or n (%).
Table 1: Baseline characteristics
Figure 1: Study proﬁ le
¹¹¹In-DTPA-exendin-4=¹¹¹In-[Lys⁴⁰(Ahx-DTPA-¹¹¹In)NH2]-exendin-4. 
SPECT/CT=single-photon emission CT in combination with CT. ASVS=selective 
intra-arterial calcium stimulation and venous sampling.
30 patients with biochemically proven endogenous hyperinsulinaemic 
       hypoglycaemia and 0–1 suspect lesions on conventional imaging
30 underwent ¹¹¹In-DTPA-exendin-4 SPECT/CT
30 eligible for inclusion
   5 did not undergo surgery
       2 declined
       2 no lesion detected
1 no conclusive imaging result
25 underwent surgery (including histology)
25 included in analyses
       25 in ¹¹¹In-DTPA-exendin-4 SPECT/CT analyses
       23 in CT/MRI analyses
       11 in endoscopic ultrasound analyses
         7 in ASVS
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showed intense focal ¹¹¹In-DTPA-exendin-4 uptake 4 h 
after injection. In ﬁ ve patients (patients 14, 19, 25, 26, and 
30) only late scans at or after 3 days showed more 
conclusive results. Histological evaluation in these ﬁ ve 
patients showed small insulinomas (7–11 mm) in four 
patients and no conclusive result in one patient. 
GLP-1R imaging was done in all 25 evaluated patients, 
showing focal radiotracer uptake in 23 patients (92%). 
¹¹¹In-DTPA-exendin-4 SPECT/CT correctly detected the 
insulinoma in 19 of 20 patients (95% sensitivity, 95% CI 
75–100). The technique had four false positive results 
(two adult nesidioblastosis and two uncharacterised 
lesions) resulting in a PPV of 83% (95% CI 62–94; table 2). 
¹¹¹In-DTPA-exendin-4 SPECT/CT was more sensitive 
than CT/MRI (table 2). Table 2 and ﬁ gure 2 summarise 
sensitivity, speciﬁ city, PPV, and diagnostic odds ratios for 
CT/MRI and ¹¹¹In-DTPA-exendin-4 SPECT/CT.
25 (83%) of 30 patients had a surgical procedure with 
histological analysis (ﬁ gure 1, table 3). Surgical planning 
was based on all available imaging results. All patients had 
surgery less than 5 weeks after imaging. 20 insulinomas 
(median size 14 mm [IQR 10–16]) were conﬁ rmed 
histologically, including two patients with multiple 
endocrine neoplasia type 1 (MEN1) and two patients with 
malignant insulinoma. Both patients with malignant 
insulinoma had only one local lymph-node metastasis. In 
the remaining ﬁ ve patients, changes compatible with adult 
nesidioblastosis (islet-cell hyperplasia) were diagnosed 
(three patients), or a deﬁ nite diagnosis (two patients) could 
not be established despite use of intraoperative ultrasound, 
palpation, and biopsy sampling.
Two patients had a conﬁ rmed germline mutation of 
MEN1. For both patients, GLP-1R imaging was positive, 
with one lesion identiﬁ ed in the tail of the pancreas 
(15 mm) in one patient and two positive lesions identiﬁ ed 
in the other patient (33 mm and 17 mm; ﬁ gure 3). Both 
patients underwent successful operations on the basis of 
preoperative localisation. Because of the localisation of the 
two lesions in the second patient, a simultaneous Whipple 
procedure and a left-sided partial pancreatectomy was 
done, whereas in the ﬁ rst patient the positive lesion in the 
tail of the pancreas was removed. Positive lesions noted on 
GLP-1R imaging in both patients were conﬁ rmed as 
insulinomas on histopathological examination. In 
addition, histological assessment in the ﬁ rst patient 
detected two microadenomas of less than 2 mm with 
insulin staining, which were not detected on GLP-1R 
imaging or other imaging modalities. In the second patient 
(patient 29), one further insulin-staining microadenoma 
(4 mm), one glucagon-staining tumour (25 mm), and two 
gastrin-staining tumours (9 mm and 6 mm) were 
identiﬁ ed, which were not identiﬁ ed on GLP-1R imaging 
or other imaging strategies.
Five patients did not undergo a surgical intervention 
(ﬁ gure 1, table 3). Two (patients 18 and 28) had negative 
conventional imaging and GLP-1R imaging results. 
Another patient (patient 2) had a negative GLP-1R scan, 
positive ASVS, and diﬀ usely enhanced uptake in the 
pancreas with ¹⁸F-ﬂ uorodopa (¹⁸F-DOPA)-PET imaging 
(data not shown), suggesting islet-cell hyperplasia 
Figure 3: Whole-body planar image (A) and SPECT/CT images (B and C) from patient 29, 4 h after injection of 
108 MBq ¹¹¹In-DTPA-exendin-4.
Focal ¹¹¹In-DTPA-exendin-4 uptake in the head of pancreas (arrowhead) and in the body of the pancreas (arrows). 
Surgery conﬁ rmed an insulinoma in head of pancreas (17 mm) and in the body of pancreas (33 mm). In the tail of 
pancreas a glucagon-producing neuroendocrine tumour (25 mm) was not detected with GLP-1R imaging. 
Additional small tumour lesions <10 mm (insulinoma and gastrinomas) were also not detected. 
¹¹¹In-DTPA-exendin-4=¹¹¹In-[Lys⁴⁰(Ahx-DTPA-¹¹¹In)NH2]-exendin-4.
BA
C
Figure 2: Contingency tables of conventional imaging and histology (A) and GLP-1R imaging with histology (B)
GLP-1R=glucagon-like peptide-1 receptor. +=positive. –=negative. 
+ 419
B   25 patients
23
GL
P-
IR
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ag
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g
–+ Total
– 11 2
Total 520 25
+ 09 9
–+ Total
– 410 14
Total 419 23
A   23 patients Histology
CT
/M
RI
Histology
¹¹¹In-DTPA-exendin-4 
SPECT/CT (n=25)
¹¹¹In-DTPA-exendin-4 
SPECT/CT (n=23*)
CT/MRI (n=23*) p value*
Sensitivity 95% (75–100) 95% (74–100) 47% (27–68) 0·011
Speciﬁ city 20% (2–64)† 25% (3–71)† 100% (45–100)† 1·0†
Positive predictive value 83% (62–94) 86% (65–96) 100% (66–100) 0·069
Diagnostic odds ratio 4·8 (0·24–93) 6·0 (0·29–124) N/A N/A
Data are n (95% CI). N/A=not applicable because of missing false-positive results. ¹¹¹In-DTPA-exendin-4=¹¹¹In-
[Lys⁴⁰(Ahx-DTPA-¹¹¹In)NH2]-exendin-4. SPECT/CT=single-photon emission CT in combination with CT. *Based 
on 23 patients for whom complete imaging was available. †Estimates based on ﬁ ve patients in the ¹¹¹In-DTPA-
exendin-4 SPECT/CT group and four patients in the CT/MRI group.
Table 2: Comparison of GLP-1R imaging and conventional imaging in patients with suspected insulinoma
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(table 3). Two patients (patients 15 and 20) had a positive 
GLP-1R scan but declined surgical intervention. All ﬁ ve 
patients have been treated medically and followed up.
Seven (23%) of 30 patients (patients 7, 12, 21, 26, and 30 
with true-positive results and patients 5 and 11 with false-
positive results) showed evidence of an insulinoma only 
on ¹¹¹In-DTPA-exendin-4 SPECT/CT. For these seven 
patients, ¹¹¹In-DTPA-exendin-4 SPECT/CT changed the 
clinical management by reinforcing the recommendation 
for surgery. Five of these patients with a proven 
insulinoma showed a normalisation of blood glucose 
levels after surgery. In the remaining two patients, only 
CT/MRI EUS ASVS GLP-1R 
imaging
Surgery and 
histology
Final diagnosis Tumour localisation Dimension of tumours
Patient 1 TP Not done TP TP Done Malignant insulinoma Uncinate process of pancreas 
and one local lymph node 
metastasis
16 mm primary, 
15 mm metastasis
Patient 2 – – + – Not done No diagnosis N/A N/A
Patient 3 TP Not done Not done TP Done Benign insulinoma Head of pancreas 15 mm
Patient 4 TP TP Not done FN Done Malignant insulinoma Tail of pancreas and one local 
lymph node metastasis
50 mm primary, 
11 mm metastasis
Patient 5 TN Not done Not done FP Done Histology negative for 
tumours
N/A N/A
Patient 6 TN Not done Not done TN Done Islet-cell hyperplasia N/A N/A
Patient 7 FN Not done Not done TP Done Benign insulinoma Head of pancreas 15 mm
Patient 8 FN Not done TP TP Done Benign insulinoma Head of pancreas 14 mm
Patient 9 Not done TP TP TP Done Benign insulinoma Tail of pancreas 30 mm
Patient 10 TN FP FP FP Done Islet-cell hyperplasia Body and tail of pancreas N/A
Patient 11 Not done TN Not done FP Done Islet-cell hyperplasia Head of pancreas N/A
Patient 12 FN Not done Not done TP Done Benign insulinoma Head of pancreas 14 mm
Patient 13 TP Not done Not done TP Done Benign insulinoma Body of pancreas 15 mm
Patient 14 FN Not done TP TP Done Benign insulinoma Head of pancreas 9 mm
Patient 15 – – – + Not done No diagnosis, refused surgery Head of pancreas N/A
Patient 16 TP TP Not done TP Done Multiple insulinomas; MEN1 Tail of pancreas 15 mm (two additional lesions 
<2 mm were not detected)
Patient 17 FN Not done TP TP Done Benign insulinoma Uncinate process of pancreas 25 mm
Patient 18 – – – – Not done No diagnosis N/A N/A
Patient 19 TN TN FP FP Done Histology negative for 
tumours
N/A N/A
Patient 20 + Not done Not done + Not done No diagnosis refused surgery Head of pancreas N/A
Patient 21 FN FN Not done TP Done Benign insulinoma Body of pancreas 10 mm
Patient 22 FN TP Not done TP Done Benign insulinoma Head of pancreas 14 mm
Patient 23 TP Not done Not done TP Done Benign insulinoma Body of pancreas 15 mm
Patient 24 TP TP Not done TP Done Benign insulinoma Head of pancreas 19 mm
Patient 25 TP Not done Not done TP Done Benign insulinoma Tail of pancreas 11 mm
Patient 26 FN Not done Not done TP Done Benign insulinoma Body tail transition 9 mm
Patient 27 FN TP Not done TP Done Benign insulinoma Head of pancreas 9 mm
Patient 28 Not done – – – Not done No diagnosis N/A N/A
Patient 29
Tumour 1 TP TP Not done TP Done Multiple insulinomas, MEN1 Head (two lesions) and body 
of pancreas
17 mm, and 33 mm (one 
additional lesion of 4 mm was 
not detected)
Tumour 2 – – Not done – Done Multiple gastrinomas, MEN1 Duodenum (two lesions) and 
one local lymph-node 
metastasis
6 mm and 9 mm (lymph node 
metastases not measured)
Tumour 3 – – Not done – Done Glucagon-producing 
neuroendocrine tumour, 
MEN1
Tail of pancreas 25 mm
Patient 30 FN Not done Not done TP Done Benign insulinoma Body of pancreas 7 mm
EUS=endoscopic ultrasound. ASVS=selective intra-arterial calcium stimulation and venous sampling. GLP-1R=glucagon-like peptide-1 receptor. TP=true positive. –=negative. +=positive. FN=false negative. 
FP=false positive. TN=true negative. N/A=not applicable. MEN1=multiple endocrine neoplasia type 1. 
Table 3: Comparison of imaging, surgical, and histological results in 30 patients with suspected insulinoma 
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biopsies of the pancreas were done, which on histology 
showed islet-cell hyperplasia in one patient and no islet 
pathology in the second patient.
Discussion
To our knowledge, our prospective multicentre imaging 
study shows for the ﬁ rst time that GLP-1R imaging is a 
more sensitive technique than conventional imaging for 
preoperative localisation of small insulinomas (panel). 
In our study, seven patients were operated on because 
GLP-1R imaging was the only method that showed a 
suspicious lesion in the pancreas. Five of these patients 
had a conﬁ rmed insulinoma with normalisation of 
hyperinsulinism after surgery, supporting the clinical 
value of GLP-1R imaging. However, conventional imaging 
was weakly associated with an increased PPV (100%) 
compared with GLP-1R imaging (86%; p=0·069). This 
eﬀ ect was attributable to an increased rate of false positive 
results with GLP-1R imaging compared with conventional 
techniques. Invasive investigations such as endoscopic 
ultrasound and ASVS also showed false positive results.
Despite our inclusion criteria that required patients to 
have only one or no suspicious lesion on conventional 
imaging, two patients had malignant insulinoma, as 
deﬁ ned by suspicious lymph nodes identiﬁ ed 
intraoperatively and conﬁ rmed by histological assessment. 
One patient was positive on GLP-1R imaging and the 
second patient had a false negative result (the only false 
negative result on GLP-1R imaging in our study). These 
ﬁ ndings corroborate a recent report that showed a low 
detection rate of malignant insulinomas with ¹¹¹In-DTPA-
exendin-4 SPECT/CT.25 Conventional imaging, by contrast, 
detected malignant insulinomas in all patients in that 
study and our own study. Overall, these ﬁ ndings suggest 
that conventional imaging should be done ﬁ rst to exclude 
malignant disease whereas GLP-1R imaging could be 
used after negative conventional imaging.
In a proof-of-principle study,18 six patients with 
endogenous hyperinsulinaemic hypoglycaemia were 
successfully studied with ¹¹¹In-DOTA-exendin-4. 
By contrast, our study used DTPA as a chelator, mainly 
because of the straightforward labelling procedure and 
high speciﬁ c activity (90 GBq/μmol for ¹¹¹In-DTPA-
exendin-4 vs 20 GBq/μmol for ¹¹¹In-DOTA-exendin-4), 
resulting in a smaller peptide load13,18 and decreasing 
potential side-eﬀ ects (eg, nausea, hypoglycaemia). We 
noted no clinically signiﬁ cant diﬀ erences in the decrease 
in glucose concentrations between ¹¹¹In-DTPA-exendin-4 
(median decrease 1·3 mmol/L, IQR 0·8–2·1) and ¹¹¹In-
DOTA-exendin-4 (1·4 mmol/L, IQR 1·1–1·6).18 In our 
study, regular monitoring of glucose concentrations after 
injection led to no serious episodes of hypoglycaemia. 
Notably, nausea was only reported with the chelator 
DOTA and not with DTPA. Whether this side-eﬀ ect is 
related to the diﬀ erent chelators or to the lower 
concentration of exendin-4 required when DTPA is used 
as a chelator has to be proven in future studies. More 
importantly, diﬀ erent chelators do not seem to aﬀ ect the 
sensitivity of GLP-1R imaging.
For four patients, GLP-1R imaging detected false 
positive lesions. In two of these patients, intraoperative 
evaluation (palpation, ultrasound, and pancreatic biopsy 
sampling) did not reveal an insulinoma or islet-cell 
hyperplasia. The underlying reason for these ﬁ ndings 
remains unclear. Because one of these lesions was 
located in the region of the pancreatic head, Brunner’s 
gland of the duodenum (which homogeneously expresses 
GLP-1R at high density26) might have interfered. GLP-1R 
imaging of islet-cell hyperplasia yielded conﬂ icting 
ﬁ ndings with two conﬁ rmed positive and one negative 
result. Recently, in-vitro GLP-1R autoradiography of 
pancreatic tissue of patients with post-bariatric 
nesidioblastosis27 showed much the same density of 
GLP-1R in islet-cell hyperplasia as normal β cells. This 
Panel: Research in context
Systematic review
We searched PubMed for studies published in English before Feb 28, 2013, with the terms 
“insulinoma” and the conventional non-invasive imaging modalities (“computed 
tomography” and “magnetic resonance imaging”), the invasive modalities (“selective 
arterial stimulation and venous sampling” and “endoscopic ultrasonography”), and the 
available methods that use radioisotopes (“Octreoscan”, “18F-DOPA-PET”, and “GLP-1 
receptor imaging”). After exclusion of case reports and narrative reviews, we identiﬁ ed 
eight relevant prospective studies and 17 relevant retrospective studies. Only three studies 
reported use of glucagon-like peptide-1 receptors (GLP-1R) imaging in insulinomas, one 
study was our own proof-of-principle study of six patients, the second study assessed 
GLP-1R imaging only in malignant insulinoma, and the third study summarised the 
experience in 11 patients with a diﬀ erent radiotracer to our study (99mTc-HYNIC-exendin-4). 
The prospective). The prospective studies included 6–27 patients with endogenous 
hyperinsulinaemic hypoglycaemia. Sensitivities of CT/MRI for detection of insulinoma 
ranged from 37% to 59%, selective arterial calcium stimulation and venous sampling 
(ASVS) from 96% to 100%, and endoscopic ultrasound from 65% to 93%. The sensitivity 
of GLP-1R imaging was 90% and 100% in the two small studies. The retrospective studies, 
assessing between six and 237 patients, reported sensitivities of 39–75% with 
conventional non-invasive imaging, 65–92% for endoscopic ultrasound, and 87–100% for 
ASVS. The sensitivity of somatostatin receptor 2 imaging using Octreoscan (Covidien, 
Hazelwood, MO, USA) is usually low (33–50%) and inconsistent for 18F-DOPA-PET (90% in 
a prospective study and 20% in a retrospective analysis).
Interpretation
Diﬀ erent imaging modalities show a wide range of sensitivity in the detection of 
insulinomas. Contributors to this diﬀ erence (beyond the nature of the imaging 
technology itself) include local availability and competence and experience of the 
operators. Present data conﬁ rm that conventional non-invasive imaging and Octreoscan 
are less eﬀ ective than are invasive methods (endoscopic ultrasound and ASVS) for 
detection of insulinomas. However, this evidence is mainly based on retrospective 
analysis as few studies have assessed non-invasive techniques with a prospective design. 
In our prospective study of 30 patients, GLP-1R imaging was superior to conventional 
imaging in the detection of insulinoma. Furthermore, our data suggest that the 
sensitivity of GLP-1R imaging is much the same as the performance of the established 
invasive methods with their inherent risks and costs. Therefore, GLP-1R imaging could 
become a key component of the preoperative management of patients with endogenous 
hyperinsulinaemic hypoglycaemia.
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ﬁ nding corresponds to a ﬁ ve-to-six-times lower density of 
GLP-1R than is noted in insulinomas,27 thereby potentially 
explaining the negative GLP-1R scan in the present study. 
Nesidioblastosis in adults (without previous bariatric 
surgery) might vary between patients with respect to the 
number of islets, size of islets, and surface receptors; this 
variation might explain why GLP-1R imaging of islet-cell 
hyperplasia could result in positive and negative scans.
Five patients did not undergo a surgical procedure in 
our study and a ﬁ nal diagnosis could not be established 
by histology: two had positive GLP-1R scans but declined 
surgery, two patients had no positive ﬁ ndings on imaging, 
and one patient had a negative result on GLP-1R imaging, 
but a positive ﬁ nding with ASVS and  ¹⁸F-DOPA PET/CT 
suggestive of adult nesidioblastosis. Assuming the worst 
case scenario, all three patients with negative scans might 
have had a benign insulinoma that was not detectable 
with the present imaging modalities. Therefore, 
overestimation of the calculated sensitivity is possible.
Epidemiological data suggest that about 6% of 
insulinomas are genetically linked to MEN1.6 In keeping 
with previous data, two (8%) of our 25 patients who 
underwent histological assessment had a conﬁ rmed 
germline mutation of MEN1.6 In both patients, GLP-1R 
imaging was positive with one lesion in one patient and 
two positive lesions in a second patient. Histological 
assessment of both patients revealed additional insulin-
staining microadenomas not detected by GLP-1R or other 
imaging with diameters of 2–4 mm. By contrast, 
insulinomas of 7 mm and more were detected by GLP-1R 
imaging, suggesting that the minimum size for detection 
with this technique is about 7 mm. Notably, gastrin-
staining and glucagon-staining tumours were not 
detected by GLP-1R imaging, underscoring the speciﬁ city 
of the method.
This study has limitations. First, because of diﬀ erences 
in local availability, preoperative choice of investigations 
could not be standardised. However, consensus does not 
exist about use of an established MRI protocol or a 
preference for use of CT/MRI in the detection of 
insulinoma.28,29 Therefore, comparison between GLP-1R 
imaging and conventional imaging (CT/MRI) seems 
reasonable. Second, the speciﬁ city of GLP-1R imaging was 
low (20%), because of a small number of true negative 
results. This feature, in turn, is related to the high 
sensitivity of the biochemical assessment done before 
imaging procedures and underscores the fact that careful 
biochemical assessment is mandatory to beneﬁ t from the 
high sensitivity of GLP-1R imaging and to avoid false 
positive results. Third, in our study, conventional imaging 
had a tendency to underperform compared with the 
published literature.2,3,29 This discrepancy might be 
explained by the fact that many of the patients in the study 
were referred following negative conventional imaging. 
Finally the study was slightly underpowered because the 
protocol suggested 30 patients with a dropout of 10% (ie, 
27 patients) but only 23 were included in the MRT/CT 
versus GLP-1R imaging analysis. Nevertheless, the 
diﬀ erence between the imaging modalities was signiﬁ cant.
Overall, our study suggests that GLP-1R imaging is a 
more sensitive method for detection of insulinomas than 
is CT/MRI and changes clinical management in a 
substantial percentage of patients with endogenous 
hyperinsulinaemic hypoglycaemia. Our limited 
experience with insulinoma in the context of MEN1 
suggests that GLP-1R imaging can detect lesions in these 
patients. The detection of islet-cell hyperplasia by GLP-1R 
imaging is inconsistent.
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